HPAI H5N1 confirmed near Garstang and Pocklington (7 Nov)

The England situation page was last updated 7 November 2026, 19:18:29 GMT. Its changelog and “Latest situation” section both state that HPAI H5N1 was confirmed on 7 November in commercial poultry near Garstang, Wyre, Lancashire (AIV 2026/24) and near Pocklington, East Riding of Yorkshire (AIV 2026/25). Dedicated case pages were first published the same evening (Garstang 19:10:15 GMT; Pocklington 19:12:47 GMT). For each premises a 3 km protection zone and 10 km surveillance zone have been declared, and “All poultry on the premises will be humanely culled.” The 4 November Brigg, North Lincolnshire case (AIV 2026/23) remains listed, as does the earlier Biggar, Scottish Borders case (AIV 2026/22). Risk-level wording on the England page was last changed on 21 October 2026 and was not rewritten in the 7 November update.

As printed: the 7 November changelog uses a singular verb (“has been declared around the premises”) for both new cases together; the “Latest situation” section splits them (Garstang “have been declared”; Pocklington “has been declared”). The official title and body for AIV 2026/25 also print “East Riding of Yorkshire, East Riding of Yorkshire” twice.

England situation › · AIV 2026/24 Garstang › · AIV 2026/25 Pocklington ›

IXCHIQ UK marketing authorisation withdrawn; only Vimkunya remains

The JCVI advice page for UK travellers was updated 6 November 2026, 11:00 GMT (not used in yesterday’s issue). The landing-page changelog reads: “Updated to remove the IXCHIQ® vaccine from the advice after the MHRA withdrew its UK marketing authorisation. The only vaccine to protect against chikungunya authorised in the UK is the Vimkunya® vaccine.” The HTML advice itself states that on 20 October 2026, following a review by the Commission on Human Medicines, MHRA withdrew the UK marketing authorisation for the IXCHIQ live-attenuated chikungunya vaccine after reports of a number of serious adverse events in older adults. Vimkunya is described as a non-live virus-like particle (VLP) vaccine, approved by MHRA in May 2025 for people aged 12 and over (marketing authorisation holder Bavarian Nordic). JCVI “does not consider it necessary to advise additional restrictions on the use of Vimkunya®” because the safety signal has only been associated with IXCHIQ. Trial figures printed on the page: 98% seroresponse at 22 days in people aged 12–64 years, falling to 86% at 6 months; in adults over 65 years, 87% at 22 days and 76% at 6 months. JCVI noted a lack of data in pregnancy. Advice (travel sub-committee February 2025; JCVI June 2025): Vimkunya may be considered, alongside bite-avoidance, for people aged 12 and over travelling to regions with active CHIKV outbreaks; long-term or frequent travellers to regions with CHIKV transmission in the past 5 years; and laboratory staff working with CHIKV. No separate MHRA withdrawal notice was opened for this issue — the withdrawal wording is taken from these JCVI/DHSC pages only.

HTML advice › · Landing page ›

MenB PGD template version 9.0 (valid from 1 December 2026)

GOV.UK updated the template page on 6 November 2026, 09:43 GMT (changelog: “Added version 9, see page 4 for change history”). The page says the PGD supports administration of MenB vaccine to individuals from 8 weeks of age eligible for the national routine programme and to individuals for prevention of secondary cases of meningococcal group B disease. It has been updated to include Trumenba (f rLP2086) as an alternative to Bexsero where the infecting strain is confirmed or predicted not to be covered by Bexsero. Trumenba is not used for the national routine childhood programme. Version 9.0 is valid from 1 December 2026 to 1 December 2029. Practitioners “must not use this PGD template until it has been authorised in Section 2.”

The downloaded v9.0 Word file (gateway GOV-20975) gives cover fields Version v9.0, valid from 1 December 2026, review date 30 June 2028, expiry 1 December 2029. Its change-history row for V9.0 is dated 30 September 2026 (not the 6 November GOV.UK publication date). It adds Trumenba for selected secondary-case prevention; notes that Trumenba is not licensed for people under 10 years and is not recommended under one year; and, when Trumenba is recommended in an outbreak, prints a schedule of 2 doses at least 4 weeks apart (irrespective of prior Bexsero), with the first dose as soon as possible. Header XML in the file contains the words “Pending Ratification”.

Date inconsistency: GOV.UK added version 9 on 6 November 2026, while the document’s own change-history date for V9.0 is 30 September 2026. The page URL slug still says “bexsero” even though v9.0 also covers selected Trumenba use.

PGD page › · v9.0 Word file ›

Statement on the attack in Cantine-Aloya, North Kivu

Africa CDC published a statement on 8 November 2026 at 05:52 GMT (dateline Addis Ababa, 8 November 2026). It “strongly condemns the deadly attack on civilians in Cantine-Aloya, North Kivu, DRC, on 5 November 2026, reportedly carried out by the Allied Democratic Forces (ADF).” It said the attack “comes at a critical moment in the response to the ongoing Ebola outbreak,” that health facilities have been attacked, and that patients, “including hundreds people with confirmed or suspected Ebola infection, have fled in search of safety” (wording as printed). It warned that interruptions to patient care, contact tracing and surveillance create additional risks, and called for a “corridor of peace,” protection of civilians, patients, health workers and health facilities, and respect for healthcare under international humanitarian law. The statement did not give new confirmed-case or death totals. It is Ebola-response/security context, not a new epidemiological sitrep, and is not today’s lead.

Africa CDC statement › · French version ›

Bundibugyo virus disease — DRC, Kenya and Nigeria (unchanged)

No newer DON this morning (DON626–628 all 404). DON625 remains as published 6 Nov 20:42 GMT (last modified 20:54 GMT). As of 3 Nov 2026: 10,668 confirmed cases and 5,198 deaths in DRC (CFR 48.7%); 2,881 recoveries; 67 health zones / 8 provinces; 51 zones with cases in the preceding 21 days. +964 confirmed / +511 deaths since DON622. No new Kenya or Nigeria cases since DON622. WHO still notes UK and Swiss medical evacuations of confirmed cases among citizens, advises against travel or trade restrictions, and says the rapid risk assessment is being revised.

DON625 ›

Multi-country outbreak page: 10,741 / 5,230 as of 5 Nov

ECDC’s multi-country Ebola page was last updated “6 November at 16.10” (before yesterday’s compilation; not used in that issue). It states that as of 5 November 2026 DRC has reported 10,741 confirmed cases, including 5,230 related deaths (from data up until 4 November) — +73 cases and +32 deaths versus DON625’s 3 November cut. Same eight provinces, explicitly including Nord Ubangi. Kenya: as of 26 October, nine confirmed cases including two deaths, all linked to the first case; last case 20 October; second death 23 October. Nigeria: case reported 20 October and medically evacuated to Switzerland; as of 4 November, 62 contacts under follow-up. EU/EEA: four cases since May 2026 linked to the DRC outbreak (three medically evacuated — two to Germany, one to the Netherlands — and a fourth reported in France in July), all in people working in healthcare or humanitarian roles in affected areas of DRC. Risk language is unchanged: likelihood of infection for EU/EEA people living in or travelling to affected areas estimated as low; for people living in the EU/EEA, very low. Do not present 10,741 / 5,230 as a WHO figure.

ECDC multi-country page ›

Ireland integrated bulletin week 44 — headline figures now extracted

Not a new bulletin (still published 5 Nov 2026; no week 45; the bulletin says it is currently published fortnightly). Yesterday listed it without digitising the tables. Prepared 05/11/2026 for ISO week 44 (26/10/2026–01/11/2026). Printed caveat: data “may be impacted due to ongoing industrial action” since 30 September 2026, and bed-occupancy data are incomplete for the same reason.

Key messages as printed: influenza activity “stabilised and remained at baseline-low levels overall”; RSV increased slightly but remained baseline-low; COVID-19 increased but remained low-moderate; rhino/enterovirus detections high, particularly in paediatrics. Sentinel GP ARI 56.6/100,000 (below baseline; highest in 0–4 years: 223.9/100,000); sentinel GP ILI 9.9/100,000 (below baseline). Influenza positivity 14%; SARS-CoV-2 12%; rhino/enterovirus 21%. COVID-19: 191 cases, 79 hospitalisations in week 44 (incidence 3.7/100,000). Influenza: 123 cases, 33 hospitalisations (incidence 2.4/100,000); influenza A(H1)pdm09 accounted for most subtyped influenza A viruses season to date. RSV: 18 cases, five hospitalisations. No overall excess all-cause mortality from week 40 2026 onwards (EuroMOMO, deaths registered to 1 November 2026).

Week 44 bulletin › · Index ›